At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
In Brief
A Phase 2 clinical trial evaluating SEA-CD40, pembrolizumab (KEYTRUDA®), and 2 other interventions for Melanoma and Carcinoma, Non-Small- Cell Lung. Completed, enrolled 77 participants across 29 sites in 6 countries.
Detailed Summary
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.
Study Details
Timeline
Interventions
Given into the vein (IV; intravenously); schedule is cohort-specific
Given by IV; schedule is cohort-specific.
Given by IV on Day 1 of each 21-day cycle.
Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.